Impact of stopping therapy during the SARS-CoV-2 pandemic in persons with lymphoma.
Shenmiao YangDong DongHongfei GuRobert Peter GaleJun MaXiaojun HuangPublished in: Journal of cancer research and clinical oncology (2020)
During the SARS-CoV-2 pandemic, lymphoma patients and their caregivers had significantly higher incidences of anxiety compared with normals. Lymphoma respondents reported better HRQoL compared with pre-pandemic controls. Reduced therapy intensity in persons with cancer may have unanticipated adverse effects on anxiety and HRQoL. Regular and intense support by caregivers and online education programmes alleviate anxiety and improve HRQoL.
Keyphrases
- sars cov
- diffuse large b cell lymphoma
- respiratory syndrome coronavirus
- end stage renal disease
- palliative care
- sleep quality
- coronavirus disease
- chronic kidney disease
- ejection fraction
- healthcare
- peritoneal dialysis
- papillary thyroid
- stem cells
- health information
- physical activity
- cell therapy
- high intensity
- quality improvement
- squamous cell
- adverse drug
- lymph node metastasis
- electronic health record
- childhood cancer